

# J Brooks Jackson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2135159/publications.pdf>

Version: 2024-02-01

171  
papers

11,140  
citations

41258

49  
h-index

30848

102  
g-index

174  
all docs

174  
docs citations

174  
times ranked

6700  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epstein-Barr virus infection status among first year undergraduate university students. <i>Journal of American College Health</i> , 2022, 70, 22-25.	0.8	8
2	SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103326.	0.5	10
3	Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. <i>Microbiology Spectrum</i> , 2022, 10, e0267621.	1.2	1
4	Analysis of entire hepatitis B virus genomes reveals reversion of mutations to wild type in natural infection, a 15-year follow-up study. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105184.	1.0	4
5	SARS-CoV-2 Infection during Pregnancy in a Rural Midwest All-delivery Cohort and Associated Maternal and Neonatal Outcomes. <i>American Journal of Perinatology</i> , 2021, 38, 614-621.	0.6	13
6	COVID-19 convalescent plasma; time for goal directed therapy?. <i>Transfusion</i> , 2021, 61, 1654-1656.	0.8	2
7	Prevalence of maternal obesity at delivery and association with maternal and neonatal outcomes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, , 1-8.	0.7	4
8	Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1351-1357.	0.6	30
9	COVID-19 convalescent plasma: phase 2. <i>Transfusion</i> , 2020, 60, 1332-1333.	0.8	23
10	NIH funding trends to US medical schools from 2009 to 2018. <i>PLoS ONE</i> , 2020, 15, e0233367.	1.1	17
11	The academic health center (AHC) chief academic officer (CAO) role in fostering interprofessional learning experiences. <i>Journal of Interprofessional Education and Practice</i> , 2019, 16, 100270.	0.2	0
12	The association between United States Medical Licensing Examination scores and clinical performance in medical students. <i>Advances in Medical Education and Practice</i> , 2019, Volume 10, 209-216.	0.7	16
13	Diagnostic utility of telomere length testing in a hospital-based setting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2358-E2365.	3.3	165
14	Relationships of demographic variables to USMLE physician licensing exam scores: a statistical analysis on five years of medical student data. <i>Advances in Medical Education and Practice</i> , 2018, Volume 9, 39-44.	0.7	23
15	The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation. <i>Academic Pathology</i> , 2018, 5, 2374289518777463.	0.7	11
16	Short telomere syndromes cause a primary T cell immunodeficiency. <i>Journal of Clinical Investigation</i> , 2018, 128, 5222-5234.	3.9	82
17	The Johns Hopkins Department of Pathology Novel Organizational Model: A 25-Year-Old Ongoing Experiment. <i>Academic Pathology</i> , 2018, 5, 2374289518811145.	0.7	7
18	The association of USMLE Step 1 and Step 2 CK scores with residency match specialty and location. <i>Medical Education Online</i> , 2017, 22, 1358579.	1.1	65

#	ARTICLE	IF	CITATIONS
19	Association between the Medical College Admission Test scores and Alpha Omega Alpha Medical Honors Society membership. <i>Advances in Medical Education and Practice</i> , 2017, Volume 8, 627-632.	0.7	5
20	Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics. <i>Proteomics</i> , 2016, 16, 1872-1880.	1.3	10
21	Do MCAT scores predict USMLE scores? An analysis on 5 years of medical student data. <i>Medical Education Online</i> , 2016, 21, 31795.	1.1	46
22	Front cover: Identification of glycoproteins associated with HIV latently infected cells using quantitative glycoproteomics. <i>Proteomics</i> , 2016, 16, NA-NA.	1.3	0
23	Laboratory Diagnostics Market in East Africa: A Survey of Test Types, Test Availability, and Test Prices in Kampala, Uganda. <i>PLoS ONE</i> , 2015, 10, e0134578.	1.1	22
24	Most Clinical Laboratory Testing in Kampala Occurs in High-Volume, High-Quality Laboratories or Low-Volume, Low-Quality Laboratories. <i>American Journal of Clinical Pathology</i> , 2015, 143, 50-56.	0.4	12
25	The Pathology Residency Program of the Johns Hopkins University School of Medicine: A Model of Its Kind. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 400-406.	1.2	7
26	Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine+Naloxone. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 554-561.	0.9	33
27	Glycoproteomic Study Reveals Altered Plasma Proteins Associated with HIV Elite Suppressors. <i>Theranostics</i> , 2014, 4, 1153-1163.	4.6	15
28	Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1-Infected Women in Uganda (HPTN 027). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 268-277.	0.9	13
29	Prevalence and Seroincidence of Hepatitis B and Hepatitis C Infection in High Risk People Who Inject Drugs in China and Thailand. <i>Hepatitis Research and Treatment</i> , 2014, 2014, 1-5.	2.0	7
30	Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. <i>Drug and Alcohol Dependence</i> , 2014, 142, 139-145.	1.6	7
31	Glycoform Analysis of Recombinant and Human Immunodeficiency Virus Envelope Protein gp120 via Higher Energy Collisional Dissociation and Spectral-Aligning Strategy. <i>Analytical Chemistry</i> , 2014, 86, 6959-6967.	3.2	52
32	Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 366-374.	0.9	24
33	Improving laboratory data entry quality using Six Sigma. <i>International Journal of Health Care Quality Assurance</i> , 2013, 26, 496-509.	0.2	15
34	Cost of Annual Tuberculosis Screening of Healthcare Workers with Negative Tuberculin Skin Test Results. <i>Infection Control and Hospital Epidemiology</i> , 2013, 34, 642-643.	1.0	0
35	Pooled Individual Data Analysis of 5 Randomized Trials of Infant Nevirapine Prophylaxis to Prevent Breast-Milk HIV-1 Transmission. <i>Clinical Infectious Diseases</i> , 2013, 56, 131-139.	2.9	19
36	Long-Term Follow-Up of Children in the HIVNET 012 Perinatal HIV Prevention Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 464-471.	0.9	23

#	ARTICLE	IF	CITATIONS
37	The Good, the Bad, and the Unknown: Quality of Clinical Laboratories in Kampala, Uganda. PLoS ONE, 2013, 8, e64661.	1.1	41
38	External Quality Assurance Performance of Clinical Research Laboratories in Sub-Saharan Africa. American Journal of Clinical Pathology, 2012, 138, 720-723.	0.4	19
39	Reply to "Were the Interests of the Vulnerable Truly Served? The Predictable Failure of HIV Immune Globulin" Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e10-e12.	0.9	0
40	Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. International Journal of Drug Policy, 2012, 23, 162-165.	1.6	10
41	The human immunodeficiency virus's genotype diversity and drug resistance mutations profile of volunteer blood donors from Chinese blood centers. Transfusion, 2012, 52, 1041-1049.	0.8	20
42	Seroprevalence of unexpected red blood cell antibodies among pregnant women in Uganda. Immunohematology, 2012, 28, 115-117.	0.2	4
43	Safety and Efficacy of HIV Hyperimmune Globulin for Prevention of Mother-to-Child HIV Transmission in HIV-1-Infected Pregnant Women and Their Infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 399-407.	0.9	42
44	Strengthening Public Laboratory Service in Sub-Saharan Africa: Uganda Case Study. Laboratory Medicine, 2011, 42, 719-725.	0.8	29
45	Association of HIV Diversity and Survival in HIV-Infected Ugandan Infants. PLoS ONE, 2011, 6, e18642.	1.1	16
46	Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based pap preparation. Diagnostic Cytopathology, 2010, 38, 555-563.	0.5	7
47	Analysis of HIV Tropism in Ugandan Infants. Current HIV Research, 2010, 8, 498-503.	0.2	8
48	Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 20-27.	0.9	66
49	Pregnancy Does Not Affect HIV Incidence Test Results Obtained Using the BED Capture Enzyme Immunoassay or an Antibody Avidity Assay. PLoS ONE, 2010, 5, e13259.	1.1	7
50	Validation of Rapid HIV Antibody Tests in 5 African Countries. Journal of the International Association of Providers of AIDS Care, 2010, 9, 170-172.	1.2	37
51	Cost of Quality at a Clinical Laboratory in a Resource-Limited Country. Laboratory Medicine, 2010, 41, 429-433.	0.8	20
52	Analysis of HIV Diversity Using a High-Resolution Melting Assay. AIDS Research and Human Retroviruses, 2010, 26, 913-918.	0.5	24
53	Considerations in Using US-Based Laboratory Toxicity Tables to Evaluate Laboratory Toxicities Among Healthy Malawian and Ugandan Infants. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 58-64.	0.9	13
54	Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors. AIDS Research and Human Retroviruses, 2009, 25, 701-705.	0.5	7

#	ARTICLE	IF	CITATIONS
55	Comparison of Laboratory Methods for Analysis of Non-nucleoside Reverse Transcriptase Inhibitor Resistance in Ugandan Infants. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 657-663.	0.5	11
56	Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan motherâ€‘infant pairs. <i>Aids</i> , 2009, 23, 1903-1908.	1.0	24
57	Lack of Antimicrobial Activity by the Antiretroviral Drug Nevirapine against Common Bacterial Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3606-3607.	1.4	3
58	Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2009, 83, 9731-9742.	1.5	41
59	The association of gender, age, body mass index, and vital signs in healthy plateletpheresis donors. <i>Transfusion and Apheresis Science</i> , 2009, 41, 175-178.	0.5	1
60	<i>In Utero</i> HIV Infection Is Associated with an Increased Risk of Nevirapine Resistance in Ugandan Infants Who Were Exposed to Perinatal Single Dose Nevirapine. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 673-677.	0.5	16
61	Predictors of Early and Late Mother-to-Child Transmission of HIV in a Breastfeeding Population: HIV Network for Prevention Trials 012 Experience, Kampala, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 32-39.	0.9	32
62	CMV antibody prevalence and seroincidence in plateletpheresis donors. <i>Journal of Clinical Apheresis</i> , 2008, 23, 63-65.	0.7	16
63	Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. <i>Lancet, The</i> , 2008, 372, 300-313.	6.3	243
64	Analysis of Nevirapine Resistance Mutations in Cloned HIV Type 1 Variants from HIV-Infected Ugandan Infants Using a Single-Step Amplification-Sequencing Method (AmpliSeq). <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1209-1213.	0.5	4
65	HIVâ€™1 Tropism and Survival in Vertically Infected Ugandan Infants. <i>Journal of Infectious Diseases</i> , 2008, 197, 1382-1388.	1.9	33
66	Comparison of Results Obtained with Amplicor HIV-1 DNA PCR Test Version 1.5 Using 100 versus 500 Microliters of Whole Blood. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1104-1105.	1.8	11
67	Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical Transmission. <i>Journal of Infectious Diseases</i> , 2008, 198, 1075-1082.	1.9	54
68	Estimate of Infant HIV-Free Survival at 6 to 8 Weeks of Age Due to Maternal Antiretroviral Prophylaxis in Sub-Saharan Africa, 2004-2005. <i>Journal of the International Association of Providers of AIDS Care</i> , 2008, 7, 133-140.	1.2	4
69	Total Lymphocyte Count: Not a Surrogate Marker for Risk of Death in HIV-Infected Ugandan Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 171-178.	0.9	3
70	Associations of Chemokine Receptor Polymorphisms With HIV-1 Mother-to-Child Transmission in Sub-Saharan Africa: Possible Modulation of Genetic Effects by Antiretrovirals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 259-265.	0.9	32
71	Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations. <i>Journal of Virology</i> , 2007, 81, 7885-7893.	1.5	149
72	Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. <i>Aids</i> , 2007, 21, 2077-2082.	1.0	16

#	ARTICLE	IF	CITATIONS
73	Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. <i>Aids</i> , 2007, 21, 1165-1174.	1.0	52
74	HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China. <i>Substance Abuse</i> , 2007, 27, 53-61.	1.1	16
75	Short Communication:HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 764-768.	0.5	13
76	Persistence of K103N-Containing HIV-1 Variants after Single-Dose Nevirapine for Prevention of HIV-1 Mother-to-Child Transmission. <i>Journal of Infectious Diseases</i> , 2007, 195, 711-715.	1.9	75
77	Late Postnatal Transmission of HIV-1 and Associated Factors. <i>Journal of Infectious Diseases</i> , 2007, 196, 10-14.	1.9	68
78	The Costs Associated With Adverse Event Procedures for an International HIV Clinical Trial Determined by Activity-Based Costing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 426-432.	0.9	12
79	HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. <i>International Journal of Infectious Diseases</i> , 2007, 11, 318-323.	1.5	27
80	Demographic characteristics and risk behaviors associated with HIV positive injecting drug users in Xinjiang, China. <i>Journal of Infection</i> , 2007, 54, 285-290.	1.7	31
81	Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 430-432.	1.2	52
82	Comparison of HIV-1 Mother-to-Child Transmission After Single-Dose Nevirapine Prophylaxis Among African Women With Subtypes A, C, and D. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 518-521.	0.9	19
83	Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. <i>Aids</i> , 2006, 20, 637.	1.0	5
84	HIV prevalence among injection drug users in rural Guangxi China. <i>Addiction</i> , 2006, 101, 1493-1498.	1.7	26
85	Quantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and D. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 610-613.	0.9	82
86	Development of Nevirapine Resistance in Infants Is Reduced by Use of Infant-Only Single-Dose Nevirapine plus Zidovudine Postexposure Prophylaxis for the Prevention of Mother-to-Child Transmission of HIV-1. <i>Journal of Infectious Diseases</i> , 2006, 193, 479-481.	1.9	46
87	Phenotypic Drug Resistance Patterns in Subtype A HIV-1 Clones with Nonnucleoside Reverse Transcriptase Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 289-293.	0.5	20
88	Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 24-29.	0.9	52
89	Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. <i>Aids</i> , 2005, 19, 2167-2169.	1.0	90
90	Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART. <i>HIV Clinical Trials</i> , 2005, 6, 262-271.	2.0	2

#	ARTICLE	IF	CITATIONS
91	Effect of periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency virusâ€“infected children in Uganda: A controlled clinical trial. <i>Nutrition</i> , 2005, 21, 25-31.	1.1	73
92	Nevirapine (NVP) Resistance in Women with HIVâ€“1 Subtype C, Compared with Subtypes A and D, after the Administration of Singleâ€“Dose NVP. <i>Journal of Infectious Diseases</i> , 2005, 192, 30-36.	1.9	193
93	Sensitive Drugâ€“Resistance Assays Reveal Longâ€“Term Persistence of HIVâ€“1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Singleâ€“Dose NVP: HIVNET 012. <i>Journal of Infectious Diseases</i> , 2005, 192, 24-29.	1.9	184
94	Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 817.	3.8	323
95	Genetic Linkage of Nevirapine Resistance Mutations in HIV Type 1 Seven Days after Single-Dose Nevirapine. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 319-324.	0.5	4
96	Comparison of Versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR Test for Subjects with Low Viral Load. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2774-2776.	1.8	9
97	Late Postnatal Transmission of HIVâ€“1 in Breastâ€“Fed Children: An Individual Patient Data Metaâ€“Analysis. <i>Journal of Infectious Diseases</i> , 2004, 189, 2154-2166.	1.9	442
98	Analysis of Insertions and Deletions in the gag p6 Region of Diverse HIV Type 1 Strains. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1119-1125.	0.5	35
99	Comparison of Nevirapine (NVP) Resistance in Ugandan Women 7 Days vs. 6â€“8 Weeks after Single-Dose NVP Prophylaxis: HIVNET 012. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 595-599.	0.5	63
100	HIVNET 012 and Petra. <i>Lancet, The</i> , 2004, 363, 244.	6.3	0
101	HIVNET 012 and Petra. <i>Lancet, The</i> , 2004, 363, 245.	6.3	1
102	Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6â€“8 Weeks After Single-Dose Nevirapine (HIVNET 012). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 126-130.	0.9	98
103	Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1253-1262.	0.9	344
104	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. <i>Lancet, The</i> , 2003, 362, 859-868.	6.3	476
105	Multicenter Evaluation of Use of Dried Blood and Plasma Spot Specimens in Quantitative Assays for Human Immunodeficiency Virus RNA: Measurement, Precision, and RNA Stability. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1888-1893.	1.8	150
106	HIV-1 Plasma RNA level and CD4 cell count in a large urban HIV-1-infected patient population from 1997 to 2000. <i>International Journal of STD and AIDS</i> , 2003, 14, 740-744.	0.5	1
107	A Modified Ultrasensitive Assay to Detect Quantified HIV-1 RNA of Fewer Than 50 Copies per Milliliter. <i>American Journal of Clinical Pathology</i> , 2003, 120, 268-270.	0.4	10
108	Granulocyteâ€“Macrophage Colonyâ€“Stimulating Factor Induces Modest Increases in Plasma Human Immunodeficiency Virus (HIV) Type 1 RNA Levels and CD4+Lymphocyte Counts in Patients with Uncontrolled HIV Infection. <i>Journal of Infectious Diseases</i> , 2003, 188, 1804-1814.	1.9	20

#	ARTICLE	IF	CITATIONS
109	A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. <i>Aids</i> , 2003, 17, 547-553.	1.0	26
110	Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq™ HIV-1 Genotyping System. <i>BioTechniques</i> , 2003, 35, 614-622.	0.8	9
111	A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliter. <i>American Journal of Clinical Pathology</i> , 2003, 120, 268-70.	0.4	6
112	Mother-to-Child Transmission in the United States of Subtypes D and A/G Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 413-417.	0.5	9
113	Identification of Ugandan HIV Type 1 Variants with Unique Patterns of Recombination in pol Involving Subtypes A and D. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 507-511.	0.5	26
114	Analysis of Length Variation in the V1-V2 Region of env in Nonsubtype B HIV Type 1 from Uganda. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 791-796.	0.5	5
115	Cross-Clade T Lymphocyte-Mediated Immunity to HIV Type 1: Implications for Vaccine Design and Immunodetection Assays. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1067-1079.	0.5	22
116	Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. <i>Annals of Tropical Paediatrics</i> , 2002, 22, 11-17.	1.0	39
117	Nucleoside Analogue Reverse Transcriptase Inhibitors Plus Nevirapine, Nelfinavir, or Ritonavir for Pretreated Children Infected with Human Immunodeficiency Virus Type 1. <i>Clinical Infectious Diseases</i> , 2002, 34, 991-1001.	2.9	74
118	Antenatal Vitamin A Supplementation Increases Birth Weight and Decreases Anemia among Infants Born to Human Immunodeficiency Virus-Infected Women in Malawi. <i>Clinical Infectious Diseases</i> , 2002, 35, 618-624.	2.9	126
119	Detection of Replication-Competent Human Immunodeficiency Virus Type 1 (HIV-1) in Cultures from Patients with Levels of HIV-1 RNA in Plasma Suppressed to Less Than 500 or 50 Copies Per Milliliter. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2089-2094.	1.8	12
120	Survival of Ugandan Infants with Subtype A and D HIV-1 Infection (HIVNET 012). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 327-330.	0.9	7
121	Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. <i>Aids</i> , 2002, 16, 1391-1400.	1.0	32
122	Iron Deficiency Anemia Is Highly Prevalent among Human Immunodeficiency Virus-Infected and Uninfected Infants in Uganda. <i>Journal of Nutrition</i> , 2002, 132, 423-429.	1.3	53
123	Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. <i>Transfusion</i> , 2002, 42, 876-885.	0.8	30
124	Nevirapine resistance after single dose prophylaxis. <i>AIDS Reviews</i> , 2002, 4, 59-63.	0.5	50
125	Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). <i>Aids</i> , 2001, 15, 1951-1957.	1.0	368
126	Relation of vitamin A and carotenoid status to growth failure and mortality among ugandan infants with human immunodeficiency virus. <i>Nutrition</i> , 2001, 17, 567-572.	1.1	34



#	ARTICLE	IF	CITATIONS
127	Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Non-Subtype B Human Immunodeficiency Virus Type 1 from Uganda. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4323-4327.	1.8	47
128	Performance of the Applied Biosystems ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Sequence-Based Analysis of HIV-1 in Pediatric Plasma Samples. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1254-1257.	1.8	51
129	Predictors of Virologic and Clinical Outcomes in HIV-1-Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320. <i>Annals of Internal Medicine</i> , 2001, 135, 954.	2.0	58
130	Safety, Tolerability, and Antiretroviral Effects of Ritonavir-Nelfinavir Combination Therapy Administered for 48 Weeks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 25, 322-328.	0.9	12
131	Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. <i>Aids</i> , 2000, 14, F111-F115.	1.0	180
132	HIV-1 ICD p24 antigen detection in Ugandan infants: Use in early diagnosis of infection and as a marker of disease progression. <i>Journal of Medical Virology</i> , 2000, 62, 426-434.	2.5	18
133	Both Serum HIV Type 1 RNA Levels and CD4+Lymphocyte Counts Predict Clinical Outcome in HIV Type 1-Infected Subjects with 200 to 500 CD4+Cells per Cubic Millimeter. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 645-653.	0.5	40
134	Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1113-1121.	0.5	77
135	Sequence Note: Analysis of HIV Type 1 Protease and Reverse Transcriptase in Antiretroviral Drug-Naive Ugandan Adults. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 807-813.	0.5	56
136	The Cost Effectiveness of a Single-Dose Nevirapine Regimen to Mother and Infant to Reduce Vertical HIV-1 Transmission in Sub-Saharan Africa. <i>Annals of the New York Academy of Sciences</i> , 2000, 918, 53-56.	1.8	11
137	Performance Characteristics of the QUANTIPLEX HIV-1 RNA 3.0 Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2837-2845.	1.8	49
138	The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. <i>Aids</i> , 1999, 13, 2269-2279.	1.0	71
139	Maternal Levels of Plasma Human Immunodeficiency Virus Type 1 RNA and the Risk of Perinatal Transmission. <i>New England Journal of Medicine</i> , 1999, 341, 394-402.	13.9	743
140	HIVNET nevirapine trials. <i>Lancet, The</i> , 1999, 354, 1818.	6.3	1
141	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. <i>Lancet, The</i> , 1999, 354, 795-802.	6.3	1,341
142	Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. <i>Lancet, The</i> , 1999, 354, 803-809.	6.3	210
143	Improved detection of human immunodeficiency virus type 1 variants by analysis of replicate amplification reactions: Relevance to studies of human immunodeficiency virus type 1 vertical transmission*. <i>Molecular Diagnosis and Therapy</i> , 1999, 4, 261-268.	1.3	7
144	A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). <i>Aids</i> , 1999, 13, 479-486.	1.0	190

#	ARTICLE	IF	CITATIONS
145	Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 545-550.	0.5	56
146	Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda. <i>Aids</i> , 1997, 11, 1823-1832.	1.0	48
147	Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1997, 336, 1487-1493.	13.9	390
148	Human immunodeficiency virus-indeterminate western blot and abortive infection. <i>Transfusion</i> , 1997, 37, 1-2.	0.8	5
149	Pentoxifylline Therapy in Human Immunodeficiency Virus-Seropositive Persons with Tuberculosis: A Randomized, Controlled Trial. <i>Journal of Infectious Diseases</i> , 1996, 174, 727-733.	1.9	73
150	Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level with Risk of Clinical Progression in Patients with Advanced Infection. <i>Journal of Infectious Diseases</i> , 1996, 174, 704-712.	1.9	176
151	Prognostic Value of Plasma Human Immunodeficiency Virus Type 1 (HIV-I) RNA Levels in Patients with Advanced HIV-I Disease and with Little or No Prior Zidovudine Therapy. <i>Journal of Infectious Diseases</i> , 1996, 174, 696-703.	1.9	99
152	The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter. <i>New England Journal of Medicine</i> , 1996, 335, 1091-1098.	13.9	502
153	Multicenter Evaluation Of Quantification Methods For Plasma Human Immunodeficiency Virus Type 1 Rna. <i>Journal of Infectious Diseases</i> , 1994, 170, 553-562.	1.9	163
154	Use of Semiquantitative Human Immunodeficiency Virus Type 1 Culture to Guide Therapy in a Premature Infant. <i>American Journal of Clinical Pathology</i> , 1994, 101, 753-755.	0.4	0
155	P2-microglobulin, HIV-1 p24 antibody and acid-dissociated HIV-1 p24 antigen levels. <i>Aids</i> , 1993, 7, 1475-1480.	1.0	17
156	A rapid manual method for CD4+ T-cell quantitation for use in developing countries. <i>Aids</i> , 1993, 7, 1565-1568.	1.0	43
157	New Testing Approaches in Transfusion Medicine. <i>Clinics in Laboratory Medicine</i> , 1992, 12, 759-770.	0.7	0
158	Hepatitis C virus antibody in HIV-1 infected Ugandan mothers. <i>Lancet, The</i> , 1991, 337, 551.	6.3	67
159	Polymerase Chain Reaction Assay for Detection of Hepatitis B Virus. <i>American Journal of Clinical Pathology</i> , 1991, 95, 442-444.	0.4	4
160	Non-isotopic polymerase chain reaction methods for the detection of HIV-1 in Ugandan mothers and infants. <i>Aids</i> , 1991, 5, 1463-1467.	1.0	24
161	The polymerase chain reaction in transfusion medicine. <i>Transfusion</i> , 1990, 30, 51-57.	0.8	22
162	Absence of HIV Infection in Blood Donors with Indeterminate Western Blot Tests for Antibody to HIV-1. <i>New England Journal of Medicine</i> , 1990, 322, 217-222.	13.9	155

#	ARTICLE	IF	CITATIONS
163	Performance Characteristics of Serologic Tests for Human Immunodeficiency Virus Type 1 (HIV-1) Antibody among Minnesota Blood Donors. <i>Annals of Internal Medicine</i> , 1989, 110, 617.	2.0	68
164	Hemophiliacs With HIV Seroconversion Associated With Heat-Treated Products: Are They Actively Infected?-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1989, 261, 1275.	3.8	4
165	Absence of HIV-1 infection in antibody-negative sexual partners of HIV- 1 infected hemophiliacs. <i>Transfusion</i> , 1989, 29, 265-267.	0.8	37
166	Recovery of Human immunodeficiency Virus from Ocular Tissues in Patients with Acquired Immune Deficiency Syndrome. <i>Ophthalmology</i> , 1988, 95, 1458-1462.	2.5	77
167	Hemophiliacs With HIV Antibody Are Actively Infected. <i>JAMA - Journal of the American Medical Association</i> , 1988, 260, 2236.	3.8	29
168	Evaluation of Two Commercial Tests for Human Immunodeficiency Virus Antigens in Culture Supernatant Fluid. <i>American Journal of Clinical Pathology</i> , 1988, 89, 788-790.	0.4	8
169	Comparison of reverse transcriptase assay with the Retro-Tek viral capture assay for detection of human immunodeficiency virus. <i>Diagnostic Microbiology and Infectious Disease</i> , 1987, 7, 185-192.	0.8	14
170	Conversion from seropositive to seronegative for cytomegalovirus antibody in plateletapheresis donors. <i>Transfusion</i> , 1986, 26, 491-492.	0.8	0
171	Granulocyte concentrates: leukapheresis vs. bone marrow aspiration. <i>Transfusion</i> , 1984, 24, 410-411.	0.8	1